The recent hantavirus cluster linked to the MV Hondius has focused attention on the Andes virus, a rare South American strain with unusual traits, and on how public health officials are weighing risk, spread and care while researchers chase treatments and vaccines.
A cluster tied to a cruise ship has produced several illnesses and fatalities, prompting lab analysis that identified the culprit as the Andes strain of hantavirus. Authorities are tracking cases and contacts while trying to pin down how this particular event unfolded aboard the vessel. Public concern is understandable but investigators are working to separate immediate facts from alarm. The situation has revived questions about transmission and geographic risk.
Most hantaviruses jump from rodents to people, usually when fresh urine, droppings or nesting materials are stirred up and inhaled. The Andes strain stands out because it has the rare ability to pass between people in limited circumstances, which changes how outbreaks are thought about. That trait does not automatically mean explosive spread, but it does demand closer attention to close contacts and symptomatic passengers. Officials emphasize targeted testing rather than broad population screening.
“The Andes strain has been increasing recently as rodents migrate north toward Buenos Aires in hot, wet climate conditions,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital. “It is predominately a rodent virus – current sequencing shows no mutations so far.”
The virus is established mainly in parts of Argentina, Chile and other areas of southern South America, where specific wild rodents carry the pathogen. Scientists point to the long-tailed pygmy rice rat and related species as the primary reservoirs that keep the virus circulating in nature. Human cases usually reflect exposure to contaminated environments rather than direct rodent bites. Travelers to endemic zones should be aware of basic rodent avoidance measures.
When the Andes strain makes someone sick it can lead to hantavirus pulmonary syndrome, a severe lung condition that causes fluid to fill the lungs and makes breathing extremely difficult. HPS is rare but dangerous, and health data show a substantial fatality rate among those who develop respiratory symptoms. Symptoms often escalate fast, so early medical attention matters for any person who develops shortness of breath after possible exposure. Hospitals provide supportive care that can be lifesaving when applied promptly.
Symptoms typically show up somewhere between four and 42 days after exposure, so timing can complicate diagnosis and contact tracing. In real-world outbreaks, people with symptoms are the ones who pose the greatest risk for onward transmission, which is why health authorities focus on symptomatic contacts. Asymptomatic spread appears to be uncommon with Andes, unlike some respiratory viruses that transmit widely before symptoms begin. That limits how broadly the virus tends to circulate once detected.
Researchers and clinicians note that person-to-person transmission of Andes is still an uncommon event based on available studies, so routine community spread remains unlikely under most conditions. The pattern observed so far suggests close, prolonged contact is usually required to transmit the virus between people. That stands in contrast to highly contagious illnesses that spread easily through casual contact or airborne routes. Public health responses therefore tend to prioritize targeted monitoring and isolation of symptomatic cases.
There is no approved specific antiviral therapy or licensed vaccine for hantavirus infections at this time, and patient care centers on supportive measures like rest, hydration and drugs to ease symptoms. Military and academic labs have active programs exploring monoclonal antibodies, and an mRNA vaccine candidate is reported to be under development. Clinical progress takes time, so immediate emphasis remains on early recognition, hospital-level supportive care and infection control practices to prevent spread.
Health agencies say the Andes virus transmits far less efficiently than routine respiratory pathogens such as measles, influenza or COVID, and they currently judge risk to the U.S. public and most travelers as very low. Testing for Andes is typically reserved for people who both have symptoms and a plausible exposure history, so blanket screening is not the standard approach. If someone believes they had contact with a confirmed case and then develops compatible symptoms, they should reach out to a medical professional or local health department right away.
